GlassScriptPhysician profile
Anjali Vaidya
NPI 1902969371
$762,012.74
in general payments reported to CMS, 2019-2025
8 companies · $173K in 2025
The $173K reported for 2025 was more than what 99% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80K · 2020: $53K · 2021: $54K · 2022: $130K · 2023: $140K · 2024: $132K · 2025: $173K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $262K · Consulting Fee: $125K · Travel and Lodging: $48K · Food and Beverage: $10K · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $261,678.55 |
| Consulting Fee | $124,784.35 |
| Travel and Lodging | $48,115.81 |
| Food and Beverage | $10,358.14 |
| Education | $107.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $341,018.19 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $190,118.58 | 2019-2025 | Tyvaso, Remodulin, Orenitram |
| Merck Sharp & Dohme LLC | $118,949.98 | 2022-2025 | Winrevair |
| Bayer Healthcare Pharmaceuticals INC. | $111,156.51 | 2019-2025 | |
| Medtronic Vascular, INC. | $324.45 | 2019 | |
| Gilead Sciences, INC. | $292.54 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $117.18 | 2022 | |
| Medtronic, INC. | $35.31 | 2023 | Resolute Onyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjali Vaidya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.